446830-63-3Relevant academic research and scientific papers
Novel Electrophilic and Photoaffinity Covalent Probes for Mapping the Cannabinoid 1 Receptor Allosteric Site(s)
Kulkarni, Pushkar M.,Kulkarni, Abhijit R.,Korde, Anisha,Tichkule, Ritesh B.,Laprairie, Robert B.,Denovan-Wright, Eileen M.,Zhou, Han,Janero, David R.,Zvonok, Nikolai,Makriyannis, Alexandros,Cascio, Maria G.,Pertwee, Roger G.,Thakur, Ganesh A.
, p. 44 - 60 (2016/01/29)
Undesirable side effects associated with orthosteric agonists/antagonists of cannabinoid 1 receptor (CB1R), a tractable target for treating several pathologies affecting humans, have greatly limited their translational potential. Recent discovery of CB1R negative allosteric modulators (NAMs) has renewed interest in CB1R by offering a potentially safer therapeutic avenue. To elucidate the CB1R allosteric binding motif and thereby facilitate rational drug discovery, we report the synthesis and biochemical characterization of first covalent ligands designed to bind irreversibly to the CB1R allosteric site. Either an electrophilic or a photoactivatable group was introduced at key positions of two classical CB1R NAMs: Org27569 (1) and PSNCBAM-1 (2). Among these, 20 (GAT100) emerged as the most potent NAM in functional assays, did not exhibit inverse agonism, and behaved as a robust positive allosteric modulator of binding of orthosteric agonist CP55,940. This novel covalent probe can serve as a useful tool for characterizing CB1R allosteric ligand-binding motifs.
ALLOSTERIC MODULATORS OF THE CANNIBINOID 1 RECEPTOR
-
Paragraph 0278, (2015/03/13)
The present technology relates to compounds and compositions of Formulas I, II, VII, and VIII, and methods using such compounds. The compounds and compositions described herein may be used in the treatment or prophylaxis of addiction, metabolic syndrome, obesity, and/or a CB1 receptor-medited disorder.
